These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 24064478

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
    Kang YM, Jung CH, Lee SH, Kim SW, Song KH, Kim SG, Kim JH, Cho YM, Park TS, Ku BJ, Koh G, Kim DM, Lee BW, Park JY.
    Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
    [Abstract] [Full Text] [Related]

  • 26. Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes.
    Tamemoto H, Ikoma A, Saitoh T, Ishikawa SE, Kawakami M.
    Diabetes Technol Ther; 2007 Jun; 9(3):246-53. PubMed ID: 17561795
    [Abstract] [Full Text] [Related]

  • 27. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD, on behalf of the EDITION 3 study investigators.
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [Abstract] [Full Text] [Related]

  • 28. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Fritsche A, Schweitzer MA, Häring HU, 4001 Study Group.
    Ann Intern Med; 2003 Jun 17; 138(12):952-9. PubMed ID: 12809451
    [Abstract] [Full Text] [Related]

  • 29. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study.
    Owens DR, Luzio SD, Sert-Langeron C, Riddle MC.
    Diabetes Obes Metab; 2011 Nov 17; 13(11):1020-7. PubMed ID: 21679291
    [Abstract] [Full Text] [Related]

  • 30. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group.
    Diabetes Obes Metab; 2009 Jun 17; 11(6):623-31. PubMed ID: 19515182
    [Abstract] [Full Text] [Related]

  • 31. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes.
    Hanefeld M, Koehler C, Hoffmann C, Wilhelm K, Kamke W, Gerstein H.
    Diabet Med; 2010 Feb 17; 27(2):175-80. PubMed ID: 20546261
    [Abstract] [Full Text] [Related]

  • 32. Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.
    Nakamura T, Sakaguchi K, So A, Nakajima S, Takabe M, Komada H, Okuno Y, Hirota Y, Nakamura T, Iida K, Kajikawa M, Nagata M, Ogawa W, Seino S.
    Diabetologia; 2015 Sep 17; 58(9):2013-9. PubMed ID: 26044206
    [Abstract] [Full Text] [Related]

  • 33. Influence of Fasting Plasma Glucose Targets on Glycemic Variability in Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of the FPG GOAL Trial (BEYOND III).
    Li L, Yang T, Xue Y, Ruan P, Du J, Li Y, Zhang X, Cui N, Yang W.
    Adv Ther; 2022 Jan 17; 39(1):421-429. PubMed ID: 34757600
    [Abstract] [Full Text] [Related]

  • 34. Effectiveness of basal-supported oral therapy (BOT) using insulin glargine in patients with poorly controlled type 2 diabetes.
    Suzuki D, Umezono T, Miyauchi M, Kimura M, Yamamoto N, Tanaka E, Kuriyama Y, Sato H, Miyatake H, Kondo M, Toyoda M, Fukagawa M.
    Tokai J Exp Clin Med; 2012 Jul 20; 37(2):41-6. PubMed ID: 22763826
    [Abstract] [Full Text] [Related]

  • 35. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
    Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD, EDITION 1 Study Investigators.
    Diabetes Care; 2014 Oct 20; 37(10):2755-62. PubMed ID: 25078900
    [Abstract] [Full Text] [Related]

  • 36. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF, Arakaki R, Jiang H, Scism-Bacon J, Anderson PW, Fahrbach JL.
    Clin Ther; 2010 May 20; 32(5):896-908. PubMed ID: 20685497
    [Abstract] [Full Text] [Related]

  • 37. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
    Fonseca V, Gill J, Zhou R, Leahy J.
    Diabetes Obes Metab; 2011 Sep 20; 13(9):814-22. PubMed ID: 21481127
    [Abstract] [Full Text] [Related]

  • 38. [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
    Yan L, Wang S, Chen P, Chen C, Shao Z, Xu X, Huang Q.
    Zhonghua Nei Ke Za Zhi; 2015 Apr 20; 54(4):307-12. PubMed ID: 26268058
    [Abstract] [Full Text] [Related]

  • 39. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.
    Clin Ther; 2007 Nov 20; 29(11):2349-64. PubMed ID: 18158076
    [Abstract] [Full Text] [Related]

  • 40. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M, Kong X, Wang H, Zhai X, Cai T, Ding B, Hu Y, Jing T, Su X, Li H, Ma J.
    J Diabetes Res; 2020 Nov 20; 2020():6666403. PubMed ID: 33299890
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.